The drug is an IL-2 receptor-directed fusion protein designed to kill IL-2R–expressing cancer cells while depleting ...

A year after it was hit with a rejection from the FDA, Citius Pharmaceuticals has won over the U.S. regulator, scoring an approval for Lymphir (denileukin diftitox-cxdl) to treat relapsed or ...

We describe two patients in whom malignant monoclonal T-cell lymphoproliferation developed after administration of chimeric antigen receptor (CAR) T-cell therapy with ciltacabtagene autoleucel ...

Chimeric antigen receptor (CAR) T cells targeting CD19 have transformed the treatment of B-cell cancers, but many patients do not have long-term remission. We designed an anti-CD19 enhanced (armored) ...

Some forms of blood cancer, such as multiple myeloma and lymphoma, are malignant diseases that originate from immune cells, specifically lymphocytes. In recent years, CAR-T cell therapies have become ...

Extreme heat and plenty of sunshine is a given for Atlanta, especially this summer. In June, there were nearly 285 hours of sunshine, and we’re on track for more rays this month, according to U.S.

Researchers discovered that lymphoma-exposed T cells accumulated excess iron, making them resistant to a type of cell death called ferroptosis. They also exhibited defects in protein quality control, ...

It’s no secret that the rate of cancer both in Australia and overseas appears to be increasing – particularly among young people. Listen to the HotCopper podcast for in-depth discussions and insights ...